CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Summary

The safety and feasibility of CAR-T cells (CD19.CAR-T) targeted at CD19 in the treatment of relapsed / refractory CD19 positive lymphoma were determined, and the proliferation and survival time of CD19.CAR-T cells in patients were determined.

Timeline

Start

2018-04-10

Primary completion

2019-04-10

Completion

2019-04-20

Drugs

Indications